Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer (Q45883136)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

1 reference

based on heuristic

inferred from title

Celestia Higano

10

object named as

C S Higano

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

author name string

K Miller

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

J W Moul

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

M Gleave

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

K Fizazi

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

J B Nelson

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

T Morris

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

F E Nathan

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

S McIntosh

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

K Pemberton

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

publication date

5 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

16

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

187-192

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

https://scigraph.springernature.com/pub.10.1038/pcan.2013.2

0 references

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Role of the endothelin axis and its antagonists in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Endothelin Inhibition: Novel Therapy for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

What do prostate cancer patients die of?

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

21 January 2018

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

31 March 2020

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

31 March 2020

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

31 March 2020

ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

31 March 2020

Emerging targeted therapies for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2013.2

31 March 2020

Identifiers

10.1038/PCAN.2013.2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23381694

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45883136&oldid=2186397685"